Filing identity and business context
Important mismatch: The supplied filing is Innovative Acquisitions Corp.’s unaudited Form 10-Q for the quarter ended June 30, 2011—not a filing by PUMA Biotechnology, Inc. The summary below reflects the filing text provided.
Innovative describes itself as a development-stage blank-check and shell company formed to pursue a business combination with an operating business. It reported no active operations other than seeking acquisition candidates, and said it had not had discussions with potential combination partners since its registration statement became effective.
Financial results and liquidity
| Metric | Three months ended June 30, 2011 | Six months ended June 30, 2011 | Comparison / balance-sheet date |
|---|---|---|---|
| Revenue | None since inception | No revenue through June 30, 2011 | |
| Net loss | $3,312 | $10,195 | Prior-year periods: $2,438 and $7,135, respectively |
| Operating cash flow | Not separately stated for the quarter | Six-month cash used: $6,915; prior year: $9,405 | |
| Cash | — | $1,747 at June 30, 2011; $462 at December 31, 2010 | |
| Accounts payable / total liabilities | — | $3,280 at June 30, 2011; zero at December 31, 2010 | |
| Stockholders’ equity (deficit) | — | $(1,533) at June 30, 2011; $462 at December 31, 2010 |
The quarterly net loss increased by $874 from the prior-year quarter; the six-month loss increased by $3,060 year over year. Losses consisted primarily of legal, accounting, audit, and other professional fees. No margin information is meaningful or provided. The filing reports no investing cash flows and no cash interest or income-tax payments. Six-month financing cash flow was $8,200, entirely from director capital contributions; no shares were issued for these contributions. No interest-bearing debt is reported.
Changes, outlook, and risks
Cash increased by $1,285 during the first half of 2011, supported by $8,200 in director contributions, while operating activities used $6,915. The company stated that it expected to incur costs for SEC reporting and investigating and pursuing an acquisition. Management anticipated relying on treasury cash, possible deferral of service-provider fees, and potential advances or investment from shareholders, management, or others. It had no binding funding arrangements and gave no assurance that funds would be available.
The financial statements explicitly state that substantial doubt exists about the company’s ability to continue as a going concern. Continuation depends on shareholder support, obtaining financing, finding a suitable target, and ultimately achieving profitable operations. The company said it had no specific acquisition timeline or plan, and acknowledged risks associated with potentially financially unstable or early-stage targets and the likely lack of diversification after a single business combination. Management reported no material change in critical accounting policies and no material off-balance-sheet arrangements. Disclosure controls were assessed as effective at June 30, 2011, with no material quarterly changes in internal controls. No material legal proceedings were reported.
Key facts for investors to verify
- Confirm the issuer identity: the supplied 10-Q names Innovative Acquisitions Corp., not PUMA Biotechnology, Inc.
- Review the going-concern disclosure and the company’s ability to fund reporting and acquisition-search costs given $1,747 in cash and $3,280 in accounts payable.
- Assess the dependence on discretionary, undocumented funding support from directors, shareholders, or other investors.
- Verify whether any acquisition discussions, target, or financing arrangements arose after the reporting period; none were reported in this filing.
- Note that the filing identifies the company as a shell company and states it had no revenue or operating business.